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Abstract
Aims/hypothesis Although cardiovascular disease is the biggest cause of death in people with diabetes, microvascular compli-
cations have a significant impact on quality of life and financial burden of the disease. Little is known about the progression of
microvascular dysfunction in the early stages of type 2 diabetes before the occurrence of clinically apparent complications. We
aimed to explore the determinants of endothelial-dependent and -independent microvascular function progression over a 3 year
period, in people with and without both diabetes and few clinical microvascular complications.
Methods Demographics were collected in 154 participants with type 2 diabetes and in a further 99 participants without
type 2 diabetes. Skin microvascular endothelium-dependent response to iontophoresis of acetylcholine and endothelium-
independent responses to sodium nitroprusside were measured using laser Doppler fluximetry. All assessments were
repeated 3 years later.
Results People with type 2 diabetes had impaired endothelial-dependent microvascular response compared with those without
(AUC 93.9 [95% CI 88.1, 99.4] vs 111.9 [102.3, 121.4] arbitrary units [AU] × min, p < 0.001, for those with vs without diabetes,
respectively). Similarly, endothelial-independent responses were attenuated in those with diabetes (63.2 [59.2, 67.2] vs 75.1
[67.8, 82.4] AU × min, respectively, p = 0.002). Mean microvascular function declined over 3 years in both groups to a similar
degree (pinteraction 0.74 for response to acetylcholine and 0.69 for response to sodium nitroprusside). In those with diabetes, use of
sulfonylurea was associated with greater decline (p = 0.022 after adjustment for co-prescriptions, change in HbA1c and weight),
whereas improving glycaemic control was associated with less decline of endothelial-dependent microvascular function (p =
0.03). Otherwise, the determinants of microvascular decline were similar in those with and without diabetes. The principal
determinant of change in microvascular function in the whole population was weight change over 3 years, such that those that
lost ≥5% weight had very little decline in either endothelial-dependent or -independent function compared with those that were
weight stable, whereas those who gained weight had a greater decline in function (change in endothelial-dependent function was
1.2 [95% CI −13.2, 15.7] AU × min in those who lost weight; −15.8 [−10.5, −21.0] AU × min in those with stable weight; and
−37.8 [−19.4, −56.2] AU × min in those with weight gain; ptrend < 0.001). This association of weight change with change in
endothelial function was driven by people with diabetes; in people without diabetes, the relationship was nonsignificant.
Conclusions/interpretation Over 3 years, physiological change in weight was the greatest predictor of change in microvascular
function.
Keywords Diabetes . Epidemiology .Microvascular . Population .Weight loss
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Abbreviations
ACh Acetylcholine
AU × min Arbitrary units × min (units for AUC of the
response curve)
CVD Cardiovascular disease
LDI Laser Doppler imager
NHS National Health Service
SNP Sodium nitroprusside
SUMMIT SUrrogate markers for Micro- and Macro-
vascular hard endpoints for Innovative diabetes
Tools
Introduction
In recent years there has been considerable focus on the
impact of type 2 diabetes on cardiovascular disease (CVD)
as the principal cause of death in people with diabetes.
Microvascular complications of diabetes, however, have a
major impact on the quality of life of people with diabetes
and are the most feared in people with diabetes [1]. Further,
both structural and functional changes in the microvasculature
significantly alter the peripheral resistance and thus haemody-
namic stress on the heart and other organs. It is thought that
this is how they play an independent part in the initiation and
progression of atherosclerotic plaques [2].
Whereas the pathophysiological mechanisms of large
artery disease have been well studied, the physiology,
mechanisms and functional changes over time at the
microvascular level are poorly understood. It is known
that determinants of microvascular disease progression
differ from those at the macrovascular level in type 2
diabetes and thus findings in the large vessels cannot be
extrapolated to small vessels [3]. The principal determi-
nants of microvascular disease progression appear to be
hyperglycaemia, and resultant advanced glycaemic end-
products (AGEs) and hyperinsulinaemia in those with
diabetes [4]. Eutrophic (inward) remodelling within the
microcirculation in response to hypertension reduces the
flow through the vessel, thereby increasing the resistance
(itself a driver for further hypertension), and limits poten-
tial for endothelially mediated relaxation of the vessels
[5]. Conversely, hypertrophic (outward) remodelling
maintains the flow, but limits the diffusion capacity of
the vessels. The respective causes of these alterations are
poorly understood; however, both result in attenuated
myogenic responses to sheer stress [6]. The clinically
measurable impact is an increased urinary AER. It is
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important to note that the urinary albumin is not itself a
disease progression determinant, but rather a measure of
systemic microvascular dysfunction.
Urinary AER, often regarded as the quantifiable hallmark of
diabetic microvascular disease, represents the presence of
substantial microvascular impairment [7, 8]. The natural history
of preclinical changes is poorly understood because of the pauci-
ty of long-term studies in relevant surrogates. The techniques
used to explore preclinical microvascular dysfunction have
developed substantially in recent times [9]. The regulatorymech-
anisms for the skin microcirculation appear to be different from
forearm blood flow [10], and responses in these two vascular
territories do not normally correlate in healthy individuals [11,
12]. The use of laser Doppler fluximetry with iontophoresis of
acetylcholine (ACh) and sodium nitroprusside (SNP) enables
mechanistic studies to non-invasively elucidate endothelial-
dependent and -independent effects [13, 14]. Skin microvascular
responses have been demonstrated to be reduced in people with
type 2 diabetes [7], and associated with left ventricular hypertro-
phy [15], urinary AER [16], retinopathy [17], coronary artery
disease [18] and symptomatic angina independent of atheroscle-
rosis [19]. A recent systematic review and network analysis
found progressivemicrovascular impairment across the spectrum
of metabolic health, from a healthy population to those with
obesity, glucose impairment and diabetes mellitus [20].
We aimed to explore the determinants of endothelial-
dependent and -independent microvascular function progres-
sion over a 3 year period, in people both with and without
diabetes and few clinical microvascular complications.
Methods
This study conformed to the Declaration of Helsinki and was
approved by the National Research Ethics Service Southwest
(10/H0206/67). All participants gave informed written
consent.
Study population Participants were adult men and women,
enhanced with individuals with type 2 diabetes and/or proven
CVD recruited as part of the ‘SUrrogate markers for Micro-
and Macro-vascular hard endpoints for Innovative diabetes
Tools’ (SUMMIT) programme (Innovative Medicines
Initiative [IMI] grant number 115006; http://www.imi-
summit.eu) via the Peninsula Research Bank, part of the
National Institute for Health Research (NIHR) Exeter
Clinical Research Facility, and the Royal Devon and Exeter
National Health Service (NHS) clinical service.
Type 2 diabetes was diagnosed according to current guide-
lines by the patients’ physicians based on an HbA1c above
48 mmol/mol (6.5%). Patients diagnosed with type 2 diabetes
under the age of 35 or treated with insulin within 12months of
diagnosis were not included in the study. CVD was defined as
previously described [7], and this included a medical history
of myocardial infarction, percutaneous coronary intervention,
coronary arterial bypass graft, unstable angina and specialist-
diagnosed cerebrovascular events from stroke and cardiology
units and clinics at the Royal Devon and Exeter Hospital, UK.
Exclusion criteria included any malignancy requiring active
treatment, any treated chronic inflammatory disease, renal
replacement therapy and end-stage renal disease.
Study visits All participants had multiple visits for both base-
line and follow-up assessments 3 years apart (mean follow-up
time: 3.14 ± 0.21 years). For both baseline and follow-up, the
microvascular studies were organised at the same time of day
or as close to this as possible.
All participants refrained from eating and drinking (except
water) for at least 2 h before the visit, and avoided smoking,
caffeine, alcohol and strenuous exercise on the study day.
Medications were omitted on the morning of the study wher-
ever possible. All vasoactive drugs were withheld for a mini-
mum of 12 h prior to the studies. Participants followed the
same protocol for medications at both visits, allowing their
results to be compared. All studies were performed in
temperature-controlled laboratories (23 ± 1°C), with the
participants lying in the supine position following an acclima-
tisation period of at least 20 min.
Screening and blood tests For both baseline and follow-up
appointments, screening assessment included anthropometry,
electrocardiogram and an interview that included medical
history and pharmacotherapy. For anthropometry, height,
weight and waist/hip ratio were measured using a standard
protocol. Brachial blood pressure was measured in the supine
position using an automated blood pressure device (Omron
M6; Omron Healthcare Europe, Hoofddorp, the Netherlands)
and the mean of three measurements was used for analysis.
All blood tests were measured from a 10 h fasting blood
sample collected on the day of the study or within a week of
the study day when not possible. Participants’ fasting glucose
and lipid concentrations were measured by the hospital’s
pathology service (Exeter Pathology Services, Royal Devon
and Exeter NHS Foundation Trust), in accordance with the
UK National Quality Assessment Scheme. Urinary AER
was measured using a timed overnight urine collection proto-
col and AER was calculated as:
albumin mg=dlð Þ  volume of urine dlð Þ  1000½ 
=time of urine collection minð Þ
Albumin was measured by the hospital’s pathology service
(Exeter Pathology Services, Royal Devon and Exeter NHS
Foundation Trust) in accordance with the UK National
Quality Assessment Scheme. Albumin/creatinine ratio was
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measured from a random spot urine sample taken on the day
of one of the visits. Analyses of albumin and creatinine
concentrations were performed using immunoturbidimetric
and Jaffe methods, respectively, with a detection limit for
albumin of 3.0 mg/l. Diabetic retinopathy was graded from
two-field photography (nasal and macular view) using the
English National Diabetic Retinopathy Grading scheme; for
the purposes of this study, diabetic retinopathy was grouped
into the following categories: no diabetic retinopathy;
nonproliferative diabetic retinopathy; proliferative diabetic
retinopathy; and previous laser treatment for proliferative
diabetic retinopathy and/or clinically significant macular
oedema. Neuropathy was assessed with a vibration perception
test on the pulp of the hallux of left and right toes using a
neurothesiometer (SLS, Nottingham, UK). A threshold of
25 V was used to define neuropathy.
Skin microvascular assessments: Iontophoresis of endothelial-
dependent (acetylcholine) and -independent (sodium nitro-
prusside) vasodilators Response to pharmacological stimula-
tion of the skin blood vessels was conducted as previously
described [7]. A solid-state laser Doppler imager (LDI)
(LDI2; Moor Instruments, Axminster, UK) was used to
measure skin perfusion, with the head of the LDI positioned
50 cm above the skin. The LDI was set to scan a region of
4.8 cm2. The LDI was interfaced with a computer equipped
with moorLDI software (Research Version 5.3). A battery-
powered iontophoresis controller (MIC 1; Moor Instruments)
was used to provide the current for iontophoresis.
After very gentle skin cleaning with alcohol wipes, Perspex
direct electrode chambers were attached to the volar aspect of
the forearm using a double-sided adhesive ring, avoiding visi-
ble veins, freckles and hair. Chambers were filled with solu-
tions under investigation; ACh (1% Miochol-E dissolved in
mannitol; Novartis, Camberly, UK) and SNP (0.25%)
(25 mg/ml Nitropress dissolved in 0.45% saline [77 mmol/l
NaCl]; Hospira, Lake Forest, IL, USA). A glass cover slip was
placed on the drug chamber to prevent reflection artefacts
from light scattered by the convex surface of the solution in
the chamber. An indifferent electrode was attached to the volar
aspect of the participant’s wrist and connected to the chamber
terminal to complete the circuit.
ACh was delivered using five pulses (100 μA each) of
anodal current with a 60 s interval between each dose (total
charge 12 mC). Perfusion was assessed at rest and then every
20 s for 6 min from the start of the charge period, with no
interval between scans.
SNP was delivered by cathodal current. A single pulse of
200 μAwas introduced for 60 s (total charge 10mC). Forearm
skin erythrocyte flux was again recorded at rest and then every
20 s for 6 min from the start of the charge period.
Median perfusion response was calculated for each image
obtained by the LDI using the total area to which the drug was
applied. Skin microvascular perfusion was measured as the
area under the response curve, normalised to resting flow,
using the trapezius rule for both ACh and SNP and expressed
in arbitrary units × min (AU × min).
Statistical analysis Analysis was performed on continuous
data to maximise power. Normality was formally assessed in
variables of interest using the Kolmogorov–Smirnov test
against theoretical distribution. Skewed variables were appro-
priately transformed, and medians [IQRs] are presented.
Statistical significance for categorical variables was calculated
using the χ2 test, and Student’s t tests or one-way ANOVA for
continuous variables, at baseline and follow-up. Where no
appropriate transformation was available, nonparametric alter-
natives (Mann–Whitney U test) were applied and median
[IQR] is presented. Differences in change over time between
groups were analysed using a two-way ANOVA (time ×
group) and pinteraction is reported. Multiple regression was used
to investigate the predictors of change over time. In exploring
mechanisms for the effect of time, potential confounding
effects of age and sex, and mechanistic factors, were consid-
ered. Mechanistic factors known to affect microvascular func-
tion included blood pressure indices (brachial systolic, brachi-
al diastolic and mean arterial pressure), body size (weight,
BMI, waist circumference and waist/hip ratio), insulin resis-
tance (fasting glucose and HbA1c) and lipid profile (total
cholesterol, LDL-cholesterol, HDL and triacylglycerols). A
single model was developed by choosing a variable from each
of these groups, based on the greatest increase in the amount
of variance explained by their inclusion in the bivariate model
against AUC for endothelial-dependent response to ACh.
Additional analyses were performed assessing the impact of
treatment with agents thought to impact vascular function,
including statins, drugs acting on the renin angiotensin system
and glucose-lowering drugs. All results of multivariate model-
ling are presented after adjustment for sex and age at baseline.
When considering the principle variables of interest in the
microcirculation, a result was deemed significant if p ≤ 0.05.
When comparing other variables between groups, p values
should be regarded as indicative.
Results
Baseline characteristics of the cohort recruited for this study
are presented in Table 1. Due to the demographics of the local
population, all participants were of white European descent.
All of the female participants were postmenopausal at recruit-
ment to the baseline visit. Those with type 2 diabetes were
slightly older and had higher BMI and HbA1c, but a more
favourable lipid profile, than those without diabetes, likely
representing more frequent statin prescription. Blood pressure
was similar in those with and without diabetes, although
almost twice as many with diabetes were receiving antihyper-
tensive therapy. People with type 2 diabetes received a variety
of glucose-lowering treatments: 20.1% were treated with diet
only, 61.7% received oral glucose-lowering medication, 5.2%
received insulin and 13.0%were treated with a combination of
oral medication and insulin.
Table 1 Baseline characteristics
of the cohort stratified by the
presence of diabetes (DM) or
absence of diabetes (No DM)
Characteristic No DM (n = 99) DM (n = 154) p
Sex (male/female) (n) 41/58 42/112 0.019
Age (years) 64.8 (63.0, 66.5) 67.9 (66.6, 69.2) 0.004
Weight (kg) 75.6 (72.9, 78.3) 91.2 (88.6, 93.8) <0.001
Height (m) 1.70 (1.68, 1.72) 1.72 (1.71, 1.73) 0.145
BMI (kg/m2)a 25.7 [23.8–27.8] 30.2 [27.6–33.6] <0.001
Waist circumference (cm) 93.1 (90.9, 95.3) 106.9 (104.9, 108.9) <0.001
Systolic BP (mmHg) 137 (133, 141) 138 (136, 140) 0.664
Diastolic BP (mmHg) 75.6 (73.8, 77.4) 76.2 (74.8, 77.5) 0.654
MAP (mmHg) 96.1 (93.9, 98.3) 96.7 (95.3, 98.2) 0.619
ABPI right 1.15 (1.12, 1.18) 1.15 (1.12, 1.17) 0.83
ABPI left 1.14 (1.11, 1.16) 1.13 (1.11, 1.16) 0.8
Total cholesterol (mmol/l)a 4.80 [4.10–5.70] 3.90 [3.30–4.50] <0.001
LDL-cholesterol (mmol/l)a 2.70 [1.98–3.31] 1.88 [1.53–2.38] <0.001
HDL-cholesterol (mmol/l)a 1.53 [1.23–1.92] 1.24 [1.06–1.43] <0.001
HbA1c (mmol/mol)
a 40 [38–42] 57 [49–67] <0.001
HbA1c (%)
a 5.7 [5.5–6.0] 7.4 [6.6–8.3] <0.001
History of CVD (%) 43.4 47.4 0.536
On antihypertensive (%) 40.4 79.2 <0.001
β-blocker 21.4 33.8 0.035
ACE-inhibitor 20.4 51.3 <0.001
Angiotensin receptor A 6.1 17.5 0.009
On statin therapy (%) 45.9 81.8 <0.001
Smoking status (%)
Current 5.1 4.6
Previous 48.0 50.7
Never 46.9 44.8 0.911
AER (μg/min)a 4.49 [3.01–6.07] 5.71 [3.88–11.65] <0.001
ACR (mg/mmol)a 0.72 [0.53–1.10] 1.07 [0.59–2.17] 0.014
Retinopathy (n)
No retinopathy NA 87 NA
Nonproliferative retinopathy NA 52 NA
Proliferative NA 0 NA
Laser treatment NA 4 NA
Unknown NA 11b NA
Neuropathy (%) NA 24c NA
Data are displayed as mean (95% CI) or median IQR
a Skewed variable; median and IQR presented and p for difference of the appropriately transformed data
b Unknown retinopathy score owing to ungradable two-field photography or data not available on clinical
database
c Defined as neurothesiometer measurement ≥25 V, available in 146 of 154 participants with type 2 diabetes
ABPI, ankle brachial pressure index; ACR, albumin/creatinine ratio; F, female; M, male; MAP, mean arterial
pressure; NA, not applicable
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Data for change in metabolic and microvascular vari-
ables over 3 years are presented in Table 2. AER was
higher at baseline and follow-up in those with diabetes
compared with those without; however, this was below
the range for clinically significant microalbuminuria
(Table 2; difference between those with and those without
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type 2 diabetes at both baseline and follow-up, p < 0.001).
Over 3 years, there was no significant increase in AER at
this preclinical level, nor was there any difference in
change over 3 years between those with and those without
diabetes (pinteraction = 0.330).
At both baseline and follow-up, endothelium-dependent
(ACh) and -independent (SNP) microvascular responses were
attenuated in people with type 2 diabetes compared with those
without (Table 2, Fig. 1a,b). Over 3 years, there was a similar
decline in meanmicrovascular function in the groups with and
without diabetes.
Determinants of change in microvascular function over the
3 years Although the average decline in group mean micro-
vascular function was similar in individuals both with and
without diabetes (age- and sex-adjusted standardised β =
0.016, p = 0.8; and −0.05, p = 0.4 for change in ACh and
SNP, respectively), there was significant diversity of magni-
tude and direction of change within the populations.
Exploring the whole cohort, percentage change in weight
accounted for the greatest variance of the model, making it
the single most predictive factor (Table 3) for the decline in
microvascular function, such that a reduction in weight was
associated with less of a deterioration of both endothelium-
dependent and -independent microvascular function, whereas
weight gain was associated with a greater decline in function.
All parameters of change in body composition and adiposity,
including absolute change in weight, change in BMI and
change in waist/hip ratio, gave similar results. Those on statin
therapy saw less of a decline in endothelium-dependent func-
tion compared with those not on statin therapy. There was no
association between change in microvascular function and
history of CVD, change in any blood pressure variable, any
blood pressure intervention (including β-blockers or modi-
fiers of the renin angiotensin aldosterone system), change in
HDL-cholesterol or change in LDL-cholesterol.
In those with diabetes alone, change in weight was the stron-
gest predictor of changes in endothelial-dependent and
-independent microvascular function (Table 3). Numerically, this
was greater by approximately a quarter for endothelial-dependent
and 45% for endothelial-independent function than in thosewith-
out diabetes, although this interaction was not statistically signif-
icant (pinteraction = 0.6 and 0.5 for ACh and SNP, respectively).
Change in glycaemic control (HbA1c) was also associated with a
modest change in endothelial-dependent microvascular function
over time, such that an increase in HbA1c was associated with a
poorer function independent of change in weight. Within a small
cohort of participants, interim HbA1c values were available. For
these individuals, we stratified into those with ‘good control’,
with a mean HbA1c < 53 mmol/mol (7.0%) over the 3 years,
and those with less good control, with a mean HbA1c >
64 mmol/mol (8.0%; electronic supplementary material [ESM]
Fig. 1). Those with good glycaemic control had less attenuation
of microvascular function over the 3 years compared with those
with poorer control (p= 0.03); however, this was accounted for
by less weight gain in those with better glycaemic control (p after
adjustment 0.2). The use of sulfonylureas (n = 46, 29.9% of the
populationwith diabetes) was associatedwith a greater decline in
endothelial microvascular function compared with those with
diabetes on other therapies, including insulin, after adjustment
for the HbA1c effect (adjusted standardised β 0.199, p = 0.02).
This association was independent of change in weight, other
diabetes therapies and duration of diabetes (adjusted standardised
β 0.198, p = 0.02). An exploratory analysis determining the
impact of going into remission from diabetes (defined as
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Fig. 1 Endothelial-dependent (a) and -independent (b) microvascular
response at baseline and follow-up in participants with andwithout diabe-
tes, over a 3 year period, measured asmicrovascular perfusion in response
to Ach (a) and SNP (b). Data are presented as the mean AUC of the
response curve (AU×min ± SEM). Two-wayANOVA (grouped by time)
was used to test interaction (a p = 0.740; b p = 0.691). (a) People with
diabetes had attenuated microvascular function in response to ACh at
baseline (***p < 0.001) and follow-up (**p < 0.01). There was signifi-
cant change in ACh over 3 years in people both with (p = 0.002) and
without type 2 diabetes (p = 0.009). (b) People with diabetes had attenu-
ated microvascular function in response to SNP at baseline (**p < 0.01)
and follow-up (***p < 0.001). There was significant reduction in SNP
over 3 years in people both with (p < 0.001) and without type 2 diabetes
(p = 0.01)
HbA1c < 48 mmol/mol [6.5%] on no glucose-lowering medica-
tions) suggested a numerical improvement in endothelial func-
tion compared with those that remained with diabetes (ESM
Table 1). However, no formal statistical analysis was performed
for this exploratory analysis due the small numbers.
Thresholds of benefit To further explore the association
between weight change and change in microvascular function,
we divided our cohort into participants who, over the 3 years of
the study, had increased, decreased or stable weight, defined as
5% or less variation (loss or gain) in their weight. The 5%
threshold in weight reduction has recently been shown to
reduce risk of cardiovascular events in patients suffering with
type 2 diabetes [21]. One hundred and ninety participants had a
stable weight and 40 participants lost 5% or more of their
weight (median 8% weight loss), including one participant
who underwent bariatric surgery, whereas 22 participants
gained 5% or more of their weight (median 7.3% weight gain).
Endothelial-dependent microvascular response to ACh did
not decline in those who lost ≥5% over the 3 years compared
with those who had stable weight, whereas those who gained
≥5% weight had an exaggerated attenuation in microvascular
function (change in endothelial-dependent function was 1.2
[95% CI −13.2, 15.7] AU × min in those who lost weight;
−15.8 [−10.5, −21.0] AU × min in those with stable weight;
and −37.8 [−19.4, −56.2] AU × min in those who put on ≥5%
weight; Fig. 2). Adjustment for age, sex, changes in blood
pressure, blood glucose and cholesterol did not change the
association (ESM Table 2). These differences were numeri-
cally similar in those with and without diabetes, although,
possibly due to the reduced power in the smaller number
without diabetes, the significance was only maintained in
those with diabetes (p = 0.025 for weight loss vs stable
weight, p < 0.001 for weight loss vs weight gain and p =
0.007 for weight gain vs weight stable). The effect of weight
loss in those with diabetes resulted in an endothelial-
dependent microvascular response after 3 years that was simi-
lar to those without diabetes who had stable weight over this
time period (response in people with diabetes who lost
weight = 101.8 AU × min vs people without diabetes who
maintained their weight 94.1 AU × min). No formal testing
was done on these comparisons.
Table 3 Association of changes
in microvascular function with
conventional cardiovascular risk
factors and treatment in the whole
population and in those with and
without diabetes after adjustment
for age and sex
Variable Change in ACh Change in SNP
Standardised β p value Standardised β p value
Whole cohort
History of CVD 0.069 0.292 −0.121 0.065
Percentage change in weight −0.248 <0.001 −0.165 0.009
Change in diastolic blood pressure −0.058 0.374 −0.030 0.647
Change in LDL-cholesterol 0.103 0.138 0.071 0.306
Statin treatment at baseline 0.160 0.016 −0.015 0.821
Diabetes-specific analysis (n = 154)a
History of CVD 0.020 0.808 −0.133 0.112
Percentage change weight −0.317 <0.001 −0.240 0.003
Change in diastolic blood pressure −0.076 0.363 −0.056 0.504
Change in LDL-cholesterol 0.016 0.853 0.034 0.704
Percentage change in HbA1c −0.203 0.014 0.082 0.329
Sulfonylurea treatmentb −0.199 0.022 −0.112 0.209
People without diabetes (n = 99)
History of CVD 0.183 0.084 −0.095 0.370
Percentage change in weight −0.160 0.117 −0.031 0.764
Change in diastolic blood pressure −0.037 0.726 −0.002 0.987
Change in LDL-cholesterol 0.235 0.033 0.109 0.313
Statin treatment at baseline 0.190 0.080 −0.137 0.209
Standardised β (i.e. SD change in variable of interest per SD change in contributing factor) from multivariate
modelling between the microcirculatory variable of interest and the mechanistic/confounding factor after adjust-
ment for age and sex. A negative standardised β represents a greater decline in microvascular function per
increase in variable (e.g. per SD increase in weight there will be ~1/4 of an SD greater decline in endothelial-
dependent microvascular function over 3 years)
a Statin therapy not considered for people living with diabetes due to co-linearity with 81% of individuals being
treated
b In a model with all glucose-lowering drugs available accounted for
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For endothelial-independent response to SNP in the whole
group, there was only a trend towards difference between those
who lost ≥5% over the 3 years and those who had stable weight
(p = 0.1). This trend appeared to be driven entirely by a signif-
icant difference in those with diabetes, such that those who lost
≥5% weight had a lower decline in SNP response compared
with those who remained weight stable (−4.5 [4.6, −13.6] vs
−16.6 [−12.0, −21.2] AU × min; p = 0.02) and those who
gained weight (−4.5 [4.6, −13.6] vs −21.3 [−9.2, −33.4] AU
× min; p = 0.03). There was no difference between those who
had stable weight and those who gained weight (p = 0.43).
Discussion
We have demonstrated for the first time that, over a 3 year
period, endothelial-dependent microvascular function
declines in weight-stable individuals, but that this decline is
attenuated with a modest amount of weight loss and acceler-
ated with a modest amount of weight gain. This was found in a
mixed cohort of people with and without type 2 diabetes.
Importantly, our findings were independent of the measures
of blood pressure and cholesterol we used and also indepen-
dent of the treatment regimens. In individuals with type 2
diabetes, change in weight and change in HbA1c were inde-
pendent predictors of change in endothelial-dependent
response, but only change in weight was associated with
change in endothelial-independent response.
The attenuation of decline in ACh responses in the absence
of an impact on SNP response in this study suggests that
weight loss is associated with an improvement in endothelial
function. This is in keeping with the growing understanding
that obesity impairs endothelial function through systemic
vascular inflammation [22].
Increased BMI and adiposity have an adverse effect on the
microcirculation, independent of diabetes, in part due to the
cellular inflammatory response to ischaemia occurring once
the hypertrophy of adipocytes is beyond the 150 μm diffusion
range of oxygen [23]. Previous studies have shown that
weight loss is associated with improvements in cyclical
changes in microvascular perfusion (vasomotion) [24] and
decreased proteinuria [25], but these studies involved signifi-
cant weight loss interventions such as gastric banding and
bypass surgery. Unlike these previous investigations, the 5%
weight loss that demonstrated benefit within our study is of
modest magnitude and achievable without drastic interven-
tions. In fact, we have shown that a weight reduction of at
least 5% or more of body weight was associated with clear
benefits in endothelial-dependent microvascular function.
Aweight loss of at least 5% has been shown to have other
beneficial effects in type 2 diabetes. Recently, for example,
this weight change threshold has been shown to be associated
with improvement in HbA1c (a finding replicated here) and a
lower 10 year hazard of CVD [21] in newly diagnosed type 2
diabetes patients. Our previous results [15] support the results
of Strelitz et al [21], suggesting that the benefits of a 5%
weight loss are wide ranging and that weight loss should be
strongly encouraged.
This study has also shown that, in people living with diabe-
tes, improving glycaemic control is associated with a lower
decline in microvascular function over 3 years. It is important
to consider whether this represents a mechanistic pathway, or
simply confounding based on shared risk factors. However,
this finding is supported by previous studies which demon-
strated that tight glycaemic control reduced microvascular
complications [26, 27]. Our study significantly adds to the
current knowledge by demonstrating that these benefits can
be realised at a stage prior to patients having microvascular
complications, and therefore should be encouraged as soon as
possible for people living with diabetes.
We found no difference in change in microvascular function
over 3 years between people with and without diabetes. This
was an unexpected finding; however, the association between
direction of glycaemic control and microvascular function
suggests that the absence of a difference may be due to
population-wide improvement in glycaemic control in the
group of individuals with diabetes, and a move away from
sulfonylurea therapy over the 3 years. It is also important to
note that, in the individuals with diabetes, lower microvascular
function at baseline remained poorer at follow-up. The benefit
of weight loss appeared to be exaggerated in thosewith diabetes
compared with those without, although this difference did not
reach statistical significance. There are several potential expla-
nations for this. It may be that the lower baseline microvascular
function in those with diabetes gives more potential for benefit
of weight loss. There may be additional benefit in people with
diabetes, given that insulin resistance is dependent on obesity,
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Fig. 2 Change in AUC in response to endothelial-dependent (ACh) stim-
ulation over 3 years stratified into those that had ≥5% weight loss, those
that were weight stable and those that gained ≥5% of their weight (AU ×
min ± SEM). p values from t tests, *p < 0.05, **p < 0.01 and
***p < 0.001
and thus weight loss improves the microvascular function
directly and indirectly through improvement in the
nonglycaemic elements of diabetes. Finally, it may simply be
coincidental, given that the study was not powered to explore
differences between those with and without diabetes but rather
to assess the impact of diabetes itself.
Strengths and limitations To our knowledge, this is the largest
study to have followed the natural history of microvascular
function in people with and without diabetes over 3 years,
who are treated in accordance with common practice within
the UK. By evaluating a general population sample, with and
without CVD, unlike the tight control that is delivered in
randomised controlled trials, these results are representative
of what a healthcare provider can reasonably expect to achieve
working with their patient population. The observational
nature, however, means it is impossible to ascribe causation.
There also remains the potential for systematic bias, in terms
of health-seeking behaviour and adherence to therapies
prescribed. This is more likely to be greater in populations
that also adhere to lifestyle suggestions. As a result, weight
loss may simply be a proxy for medication adherence.
Additionally, the study cannot exclude shared confounding
of weight loss and improvement in microvascular endothelial
function from other, unmeasured mechanistic factors,
although the failure of conventional risk factors to account
for these associations, having only a minimal effect on the
standardised βs, makes this unlikely. Further, as a secondary
analysis of a subpopulation from the SUMMIT cohort, study
power was limited for subgroup analyses. Across the whole
population with the complete microvascular dataset, we have
97% power to detect a clinically meaningful 7% variance (R2)
that was accounted for by difference in weight. Within the
diabetes subpopulation, however, this power is reduced to
84%, and further reduced to 64% for those without diabetes.
This likely accounts for the lack of significant benefit demon-
strated in the population without diabetes, despite similar
numerical benefit as in those with diabetes.
Conclusion In conclusion, we have demonstrated that modest
weight loss and good glycaemic control are associated with
less 3 year decline in microvascular function in people with
diabetes. Unlike studies in laboratory settings, where experi-
mental conditions are tightly controlled, we observed the
microvascular progression in a large group of people managed
in the community by their usual physicians and no additional
study-specific interventions. Further, we have demonstrated
that a modest weight loss of only 5% attenuated the time-
dependent decline of endothelial-dependent microvascular
function over 3 years.
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